CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01948141
NCT01948141Phase 2Completed
CompareCT.gov

FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens

Roswell Park Cancer Institute·interventional·Posted Sep 23, 2013·Updated Jun 8, 2017

In Brief

A Phase 2 clinical trial evaluating nintedanib for Recurrent Non-small Cell Lung Cancer and 3 related conditions. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Boehringer Ingelheim

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 23, 2013
Enrollment StartJan 30, 2014
Primary CompletionAug 16, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.8 years ago

Interventions

nintedanibdrug

Given PO